Medicine and Dentistry
Breast Cancer
100%
Malignant Neoplasm
43%
BRCA1
30%
BRCA2
24%
Disease
24%
Adjuvant Therapy
21%
Colorectal Cancer
20%
Epidermal Growth Factor Receptor 2
20%
Gamma Urogastrone
19%
Adjuvant Chemotherapy
18%
Neoplasm
17%
Cancer Therapy
16%
Medical Oncology
14%
Trastuzumab
14%
Consultation
13%
Metastatic Breast Cancer
13%
Cancer Diagnosis
12%
Oncology
12%
Non Small Cell Lung Cancer
12%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
11%
Metastatic Carcinoma
11%
Patient Referral
11%
Clinical Oncology
11%
Pertuzumab
11%
Tamoxifen
11%
Breast Carcinoma
10%
Pancreas Islet Cell Tumor
10%
Odds Ratio
10%
Oncologist
9%
Neoadjuvant Therapy
9%
Cancer Risk
9%
Health Care Cost
7%
Decision Making
7%
Trastuzumab Deruxtecan
7%
Retrospective Study
7%
Social Isolation
6%
Case-Control Study
6%
Ovariectomy
6%
Progesterone Receptor
6%
Estrogen Receptor
6%
Recurrent Disease
6%
Contralateral
6%
Ovarian Cancer
5%
Health Care
5%
Cardiovascular System
5%
Genetic Disorder
5%
COVID-19
5%
Cancer Susceptibility
5%
Gene Amplification
5%
Cancer Prognosis
5%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
83%
Chemotherapy
40%
Metastatic Breast Cancer
35%
Trastuzumab
23%
Doxorubicin
23%
Gamma Urogastrone
19%
Epidermal Growth Factor Receptor 2
19%
Tamoxifen
18%
Disease
17%
Cyclophosphamide
17%
Endocrine Therapy
17%
Malignant Neoplasm
17%
Exemestane
16%
Anthracycline
13%
Recurrent Disease
12%
Docetaxel
11%
Aromatase Inhibitor
11%
Epirubicin
11%
Fulvestrant
11%
Anastrozole
11%
Neoplasm
9%
Cardiotoxicity
9%
Febrile Neutropenia
8%
Clinical Trial
7%
Trastuzumab Deruxtecan
7%
Ovary Cancer
7%
Estrogen Receptor
6%
Progesterone Receptor
6%
Hormone Receptor
6%
Breast Carcinoma
5%
Cancer Prognosis
5%
Lung Toxicity
5%
Bizelesin
5%
Zoledronic Acid
5%
Pertuzumab
5%
Cancer Incidence
5%
Neuroendocrine Tumor
5%
Corticotropin
5%
Molecular Marker
5%
Testis Carcinoma
5%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
5%
Event Free Survival
5%
Bevacizumab
5%
Vandetanib
5%
Pneumonia
5%
Letrozole
5%
Solid Malignant Neoplasm
5%
Foretinib
5%
Aromatase
5%
Triple Negative Breast Cancer
5%
Keyphrases
Breast Cancer
42%
BRCA mutation Carriers
22%
Breast Cancer Risk
17%
BRCA2 mutation
16%
Cost-utility
16%
Breast
13%
Adjuvant Chemotherapy
12%
Trastuzumab
11%
Postmenopausal Women
11%
Neoadjuvant Endocrine Therapy
11%
Anastrozole
11%
Exemestane
11%
Confidence Interval
8%
Metastatic Disease
7%
Hazard Ratio
7%
Early Breast Cancer
7%
Canada
7%
Overall Survival
6%
Metastatic Breast Cancer
6%
Bilateral Oophorectomy
6%
Docetaxel
6%
Beyond Progression
6%
Adjuvant Therapy
5%
Nodal Harvest
5%
Carcinoid
5%
Solitude
5%
Oncologic Therapy
5%
Progression-free Survival
5%
Adjuvant Trials
5%
Herceptin
5%
Novel Agents
5%
AKT/mammalian Target of Rapamycin
5%
Metaplastic Breast Carcinoma
5%
Cardiotoxicity
5%
Cardiac Toxicity
5%
Redrawing
5%
Doxorubicin
5%
Breast Cancer Prognosis
5%
Triple-negative Breast Cancer
5%
Clinical Oncology
5%
Pathology Consultation
5%
Inter-institutional
5%
Therapy Recommendations
5%
Impact of Cancer
5%
Age at First Birth
5%
Ileal Neuroendocrine Tumors
5%
Taxotere
5%
Full-term Infants
5%
5-flurouracil
5%
Epirubicin
5%